WS02.3 Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD)

enthalten in: Journal of cystic fibrosis | 2015

von Olivier, K. | Eagle, G. | McGinnis, J. | +11

112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa

enthalten in: Journal of cystic fibrosis | 2015

von Bilton, D. | Pressler, T. | Fajac, I. | +11